Severe Asthma Covid Vaccine Response Study (SHINE)
SHINE: Severe Asthma Covid Vaccine Response Study
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
SARS-CoV-2 and the resulting COVID-19 pandemic has had a major impact on quality of life in people with severe asthma. Careful isolation and lockdown measures have protected many patients, but with major impacts on wellbeing and mental health. Vaccination opens a "light at the end of the tunnel" by protecting against COVID-19. However, the following questions remain unanswered for Covid vaccination in severe asthma: 1) What are patients' expectations/attitudes towards vaccination? 2) Will vaccines induce good immune responses which protect from Covid-19 infections? The first question is being addressed by a survey created SHARP, a European Clinical Research Collaboration on severe asthma- people with asthma from the UK and Europe will be invited to complete the survey. To complement this, the investigators propose a UK pilot study (carried out in up to four severe asthma centres) to measure immune responses following vaccination in 200 people with severe asthma. The investigators will invite 120 people receiving asthma biologics (monoclonal antibodies), 40 people receiving asthma inhalers, 40 people needing daily steroid tablets to control their asthma, and 50 age-matched healthy people. Immune responses will be studied using a simple home blood antibody test posted to participants. By pricking their finger, patients will collect 5-6 drops of blood in a small test tube and will post back on the same day to a laboratory in London. Tests will be done twice: after the first and second vaccine doses.
The study will help us understand if the body's immune response to the COVID-19 vaccine is different in people with severe asthma who are on different treatments to manage their symptoms.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Thomas Bower
- Telefonnummer: 02381204989
- E-post: thomas.bower@uhs.nhs.uk
Studieorter
-
-
-
Exeter, Storbritannien, EX2 5DW
- Har inte rekryterat ännu
- Royal Devon and Exeter NHS Foundation Trust
-
Kontakt:
- Lisa Treeby
- Telefonnummer: 01392 403814
- E-post: lisa.treeby@nhs.net
-
Kontakt:
- Matthew Masoli
- E-post: matthew.masoli@nhs.net
-
Huvudutredare:
- Matthew Masoli
-
Glasgow, Storbritannien, G12 0YN
- Rekrytering
- Gartnavel General Hospital
-
Huvudutredare:
- Rekha Chaudhuri
-
Kontakt:
- Rekha Chaudhuri
- E-post: Rekha.Chaudhuri@ggc.scot.nhs.uk
-
Kontakt:
- Kayleigh Mckenna
- E-post: Kayleigh.McKenna@ggc.scot.nhs.uk
-
London, Storbritannien, SE1 9RT
- Har inte rekryterat ännu
- Guy's and St Thomas' NHS Trust Foundation
-
Kontakt:
- Gill Arbane
- E-post: gill.arbane@gstt.nhs.uk
-
Kontakt:
- Mathew Furtado
- E-post: Mathew.Furtado@gstt.nhs.uk
-
Huvudutredare:
- David Jackson, MRCP MSc PhD
-
Newcastle, Storbritannien, NE1 4LP
- Har inte rekryterat ännu
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
Huvudutredare:
- Simon Doe
-
Kontakt:
- Simon Doe
- E-post: simon.doe@nhs.net
-
Kontakt:
- Jamie Brown
- E-post: jamie.brown3@nhs.net
-
-
Hampshire
-
Southampton, Hampshire, Storbritannien, SO16 6YD
- Rekrytering
- University Hospital Southampton NHS Foundation Trust
-
Kontakt:
- Thomas Bower
- Telefonnummer: 02381204989
- E-post: thomas.bower@uhs.nhs.uk
-
Huvudutredare:
- Hitasha Rupani
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion criteria:
- Age ≥ 16 years
For asthma patients:
- Diagnosis of severe asthma (based on ATS/ERS consensus criteria)
- Group A: Currently receiving an asthma biologic with treatment having started at least 3 months before first COVID-19 vaccine
- Group B: on maintenance oral steroids at a dose of ≥5mg prednisolone (or equivalent) per day (at the time of first COVID-19 vaccine)
- Group C: not on asthma biologic or maintenance oral steroids (at the time of vaccination) or stopped ≥3 months prior to first COVID-19 vaccine
Exclusion criteria:
- Current pregnancy or planning a pregnancy within the next 6 months
- Current malignancy
- Diagnosis of immunodeficiency requiring treatment
Additional exclusion criteria for asthma patients:
- Group A: maintenance oral steroids at the time of first COVID-19 vaccine
- Group B: on an asthma biologic at the time of first COVID-19 vaccine
Additional exclusion criteria for healthy controls cohort (as assessed by research team):
- No history of asthma or significant other lung disease
- Severe chronic inflammatory disease
- Severe cardiac disease
- Diabetes
- Previous proven COVID-19 infection
- Inability to provide informed consent
- Unwilling to have vaccination
- Participation in another clinical trial involving an investigational medicinal product (IMP).
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Case-Control
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Asthma biologics
120 people receiving asthma biologics (monoclonal antibodies)
|
Not Interventional their treatments are their routine NHS care
|
|
Asthma inhalers
40 people receiving asthma inhalers
|
Not Interventional their treatments are their routine NHS care
|
|
Steroid tablets
40 people needing daily steroid tablets to control their asthma
|
Not Interventional their treatments are their routine NHS care
|
|
Healthy Control
50 age-matched healthy people
|
Not Interventional their treatments are their routine NHS care
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Measured immune response
Tidsram: 12 Months
|
To compare the measured immune response to vaccination in patients with 200 severe asthma and 50 healthy individuals.
A positive response will be defined as IgG ≥0.201.
|
12 Months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Range of immune responses
Tidsram: 12 Months
|
To evaluate the range of immune responses measured by IgG titres (very high: >1.25, high: 0.751-1.25,
medium: 0.401-0.75
or low: 0.201-0.4) in patients with 200 severe asthma and compare this with 50 healthy individuals
|
12 Months
|
|
Differences in responses between treatment groups
Tidsram: 12 Months
|
To identify any differences in responses between patients treated with biologics, standard inhaler treatment with/without maintenance oral corticosteroids (mOCS)
|
12 Months
|
|
Differences between responses within the three biologics
Tidsram: 12 Months
|
To identify any differences between responses to vaccines amongst patient groups treated with three biologics (anti-IgE Omalizumab, anti-IL-5 Mepolizumab, and anti-IL-5receptor Benralizumab)
|
12 Months
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Hitasha Rupani, University Hospital Southampton NHS Foundation Trust
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RHM MED1777
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .